Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

Abbott Labs

Masimo

Veracyte

Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.

4 Healthcare Technology Innovators to Invest in Before the New Year

Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Omnicell (OMCL) Might be Well Poised for a Surge

Allstate

Carpenter Technology

DXP Enterprises

Latam Airlines Group SA

LTM, OMCL, DXPE, ALL and CRS have been added to the Zacks Rank #1 (Strong Buy) List on December 18, 2024.

New Strong Buy Stocks for December 18th

Omnicell (OMCL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Omnicell (OMCL) a New Strong Buy Stock

Finance Of America Cos

ZIM Integrated Shipping Services

ZIM, OMCL and FOA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 12, 2024.

Best Momentum Stocks to Buy for December 12th

Omnicell introduces OmniSphere. Additionally, the company showcases a full portfolio of outcomes-centric solutions at the ASHP Midyear 2024.

Omnicell Introduces OmniSphere Platform, Stock to Gain

Immunocore Holdings

NB Bancorp Inc

UL Solutions Inc

NBBK, OMCL, ZIM, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on December 12, 2024.

New Strong Buy Stocks for December 12th

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces OmniSphere; Next-generation, cloud native, software workflow engine will integrate Omnicell solutions across care settings.

Omnicell Announces OmniSphere

Butterfly Network

Clover Health Investments

Inspire Medical Systems Inc

Talkspace

Five medical info systems stocks have strong potential for 2025. These are: INSP, OMCL, TALK, BFLY, CLOV.

5 Medical Info System Stocks to Buy for a Stable Portfolio in 2025

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Why Is Omnicell (OMCL) Down 0.4% Since Last Earnings Report?

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Piper Sandler 36th Annual Healthcare Conference.

Omnicell to Present at the Piper Sandler 36th Annual Healthcare Conference

The mean of analysts' price targets for Omnicell (OMCL) points to a 26.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Omnicell (OMCL) Could Rally 26.73%: Here's is How to Trade

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering.

Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Proposed Private Placement of $150 Million of Convertible Senior Notes.

Omnicell Announces Proposed Private Placement of $150 Million of Convertible Senior Notes

A robust Advanced Services portfolio and long-term growth initiatives bode well for Omnicell.

Here's Why You Should Add OMCL Stock to Your Portfolio Now

Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock

Omnicell, Inc. is a pharmacy management provider working towards the goal of an autonomous pharmacy. Q3 earnings looked weak on the surface with revenue and EBITDA down, but results by business show a strong and growing service business. Omnicell has unique technology with strong market tailwinds that support long-term growth.

Omnicell Q3 Earnings: Look At The Growth Segment

Omnicell continues its trend of impressive results in the third quarter of 2024.

OMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Omnicell, Inc. (OMCL) Soars to 52-Week High, Time to Cash Out?

Omnicell, Inc. (NASDAQ:OMCL ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Kathleen Neiman - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President & Chief Executive Officer Nchacha Etta - Executive Vice President & Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Jessica Tassan - Piper Sandler Allen Lutz - Bank of America Stephanie Davis - Barclays Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Capital Markets Bill Sutherland - The Benchmark Company Stan Berenshteyn - Wells Fargo David Larsen - BTIG Operator Thank you for standing by. My name is John, and I'll be your conference operator today.

Omnicell, Inc. (OMCL) Q3 2024 Earnings Call Transcript

Omnicell stock broke out Wednesday after the medications management company obliterated its own earnings expectations. The post Omnicell Catapults And Breaks Out After Obliterating Profit Expectations appeared first on Investor's Business Daily.

Omnicell Catapults And Breaks Out After Obliterating Profit Expectations

Omnicell (OMCL) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.62 per share a year ago.

Omnicell (OMCL) Beats Q3 Earnings and Revenue Estimates

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Third Quarter 2024 Results.

Omnicell Announces Third Quarter 2024 Results

10X Genomics

Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.

News for Omnicell Stock (OMCL)